Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts).

被引：0
|
作者：
Muller, Martin C.
Baccarani, Michele
Deininger, Michael W. N.
Guilhot, Francois
Hochhaus, Andreas
Hughes, Timothy P.
Shah, Neil P.
Talpaz, Moshe
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Timothy Piers
Haluska, Frank G.
Cortes, Jorge E.
机构：
[1] Univ Med Mannheim, Mannheim, Germany
[2] S Orsola Malpighi Univ Hosp, Bologna, Italy
[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[4] CHU Poitiers, Inserm CIC 1402, Poitiers, France
[5] Jena Univ Hosp, Jena, Germany
[6] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia
[7] Univ Adelaide, Adelaide, SA, Australia
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Univ Michigan, Ann Arbor, MI 48109 USA
[10] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA
[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7053
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7053
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
    Jabbour, Panelelias
    Kantarjian, Hagop M.
    Koller, Paul B.
    Jamy, Omer
    Oehler, Vivian G.
    Lomaia, Elza
    Hunter, Anthony M.
    Uspenskaya, Olga
    Samarina, Svetlana
    Mukherjee, Sudipto
    Baer, Maria R.
    Zherebtsova, Vera
    Shuvaev, Vasily
    Turkina, Anna
    Davydkin, Igor
    Cortes, Jorge
    Guo, Huanshan
    Chen, Zi
    Fu, Lei
    Wang, Hengbang
    Jiang, Lixin
    Wang, Cunlin
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2023, 142
  • [42] Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
    Apperley, Jane F.
    Cortes, Jorge E.
    Jabbour, Elias
    Hochhaus, Andreas
    Hughes, Timothy
    Chuah, Charles
    de Lavallade, Hugues
    Deininger, Michael W.
    Lipton, Jeffrey H.
    Lomaia, Elza
    Maness, Lori
    Mauro, Michael
    McCloskey, James
    Moiraghi, Beatriz
    Pavlovsky, Carolina
    Rojas, Christine
    Rousselot, Philippe
    Sacha, Tomasz
    Talpaz, Moshe
    Turkina, Anna
    Sutton, Maria Undurraga
    Ren, Xiaowei
    Vorog, Alexander
    Rosti, Gianantonio
    BLOOD, 2022, 140 : 6760 - 6762
  • [43] Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd
    Saglio, Giuseppe
    Hughes, Timothy P.
    Larson, Richard A.
    Issaragrilsil, Surapol
    Turkina, Anna G.
    Steegmann, Juan Luis
    Lopez, Jose L.
    Nakaseko, Chiaki
    Kalaycio, Matt E.
    Huguet, Francoise
    Kemp, Charisse N.
    Fan, Xiaolin
    Menssen, Hans D.
    Kantarjian, Hagop M.
    Hochhaus, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.
    Shah, Neil P.
    Kantarjian, Hagop
    Kim, Dong-Wook
    Hochhaus, Andreas
    Saglio, Giuseppe
    Guilhot, Francois
    Schiffer, Charles Alan
    Steegmann, Juan Luis
    Mohamed, Hesham
    Dejardin, David
    Healey, Diane I.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial
    Apperley, Jane
    Cortes, Jorge
    Jabbour, Elias
    Hochhaus, Andreas
    Hughes, Timothy
    Chuah, Charles
    de Lavallade, Hugues
    Deininger, Michael
    Lipton, Jeffrey H.
    Lomaia, Elza
    Maness, Lori
    Mauro, Michael
    McCloskey, James
    Moiraghi, Beatriz
    Pavlovsky, Carolina
    Rojas, Christine
    Rousselot, Philippe
    Sacha, Tomasz
    Talpaz, Moshe
    Turkina, Anna
    Sutton, Maria Undurraga
    Ren, Xiaowei
    Vorog, Alexander
    Rosti, Gianantonio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S339 - S339
  • [46] Cytogenetic and Molecular Responses after 2 Years of Tyrosine Kinase Inhibitor (TKI) Treatment in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice
    Cortes, Jorge E.
    Goldberg, Stuart L.
    Michallet, Mauricette
    Hehlmann, Rudiger
    Simonsson, Bengt
    Mauro, Michael J.
    Williams, Loretta A.
    Zyczynski, Teresa
    Sen, Ginny P.
    Foreman, Aimee
    Gajavelli, Srikanth
    Gambacorti-Passerini, Carlo
    BLOOD, 2017, 130
  • [47] EARLY MOLECULAR RESPONSE PREDICTS ACHIEVEMENT OF UNDETECTABLE BCR-ABL IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB: 3-YEAR FOLLOW-UP OF ENESTCMR
    Branford, S.
    Kamel-Reid, S.
    Bendit, I.
    Etienne, G.
    Guerci-Bresler, A.
    Hughes, T. P.
    Lipton, J. H.
    Leber, B.
    Spector, N.
    Steegmann, J. L.
    Acharya, S.
    Collins, L.
    Dalal, D.
    Cervantes, F.
    HAEMATOLOGICA, 2014, 99 : 532 - 532
  • [48] The palliative role of gefitinib (IRESSA®) in the treatment of heavily pretreated patients with advanced, refractory non-small-cell lung cancer:: Results of a 3-year experience
    Scimone, A.
    Franchina, T.
    Adamo, B.
    Marabello, G.
    Spitaleri, G.
    Festa, V.
    Sacca, M. Maugeri
    Russo, A.
    Adamo, V.
    ANNALS OF ONCOLOGY, 2006, 17 : VII163 - VII163
  • [49] Impact of fixed atherosclerotic coronary lesion in patients with coronary artery spasm on 3-year clinical outcomes
    Rha, S. W.
    Choi, B. G.
    Choi, S. Y.
    Li, H.
    Choi, C. U.
    Kim, J. W.
    Kim, E. J.
    Park, C. G.
    Seo, H. S.
    Oh, D. J.
    EUROPEAN HEART JOURNAL, 2014, 35 : 319 - 319
  • [50] Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response
    Cortes, Jorge E.
    Hochhaus, Andreas
    Kim, Dong-Wook
    Shah, Neil P.
    Mayer, Jiri
    Rowlings, Philip
    Nakamae, Hirohisa
    Bradley-Garelik, M. Brigid
    Mohamed, Hesham
    Kantarjian, Hagop M.
    Saglio, Giuseppe
    BLOOD, 2013, 122 (21)
12345